Beckman Coulter Broadens Menu with Immunosuppressant Drug Reagents

Beckman Coulter Diagnostics will now distribute four new Immunosuppressant Drug (ISD) user defined reagents as part of the company’s Therapeutic Drugs Monitoring menu on its AU family of clinical chemistry systems. The assays, manufactured by Thermo Fisher Scientific, will enable laboratories to deliver vital results for the management of immunosuppressant drug therapy for organ transplant patients—specifically aiding in the management of kidney, liver and/or heart transplant patients.

The assays included in the new offering are:

• Thermo Scientific™ QMS® Everolimus (EVR)

• CEDIA® Mycophenolic Acid (MPA)

• QMS® Tacrolimus (TAC)

• CEDIA® Cyclosporine Plus (Low Range: CSAL & High Range: CSAH)

“By adding these four new, high-quality assays to Beckman Coulter’s menu, our customers can provide valuable information to help physicians establish dosing regimens, maintain therapeutic levels and detect toxic levels for transplant recipients,” said John Blackwood, senior vice president of Beckman Coulter Diagnostics Chemistry and Immunoassay Business Unit.

These products offer a comprehensive package of reagents, calibrators and controls and have received clearance for distribution in the US, Puerto Rico and EU. The new assays are available now for use on Beckman Coulter’s AU480, AU680 and AU5800 clinical chemistry systems. The AU systems follow high standards of reliability and maximum uptime with scalability. Hardware consumables, reagents and operating software are standardized across the AU family to minimize training requirements and streamline inventory management.

“Continuing our mutually beneficial relationship with Beckman Coulter results in a better user experience for laboratories,” said Marc Tremblay, president of Thermo Fisher Scientific’s Clinical Diagnostics Division. “Adding our Thermo Scientific assays with instrument specific applications to Beckman Coulter’s larger menu of assays will allow laboratorians to work more efficiently.”